Andrea Ellis - 09 Jul 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Director
Issuer ticker: BBIO
Reported as of: 09 Jul 2026
Net transaction value: -$1,442,028
SEC form: 4
Accepted by SEC: 13 Jul 2026, 16:41:33 UTC
Prior SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Will Solis, Attorney-in-Fact

Key filing fact

Andrea Ellis filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 13 Jul 2026.

Key facts

This page summarizes Andrea Ellis's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Jul 2026, 16:41.

Change

Previous filing in this sequence was filed on 24 Jun 2026.
Current net transaction value: -$1,442,028.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001877680 Primary reporting owner

Ellis Andrea

Relationship: Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Will Solis, Attorney-in-Fact
Signature date: 13 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Options Exercise

Transaction value
Shares: +17,167
Change %: +76%
Price: $16.75^*
Shares after: 39,746
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F1

BBIO transaction

Common Stock

Sale

Transaction value: $1,442,028
Shares: -17,167
Change %: -43%
Price: $84.00
Shares after: 22,579
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -17,167
Change %: -50%
Price: $0.000000^*
Shares after: 17,167
Date: 09 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,167
Exercise price: $16.75
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025.

Footnote F2

1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.